Managing IBD Therapies in Pregnancy.
Inflammatory bowel disease is frequently diagnosed before or during key childbearing years. One of the most important factors for a healthy pregnancy is having quiescent disease prior to conception and maintaining disease remission for the duration of the pregnancy. In order to achieve that, most women will need to continue their inflammatory bowel disease (IBD) treatment during pregnancy. One of the main concerns these women have is whether these medications will have adverse effects on their growing fetus. Aminosalicylates, antibiotics, and steroids are all relatively low risk for use during pregnancy and breastfeeding. Recent studies also support the safety of continuing immunomodulators and anti-tumor necrosis factor agents during pregnancy and with breastfeeding. There seems to be an increased risk for infection, however, with use of combination therapy including both a biologic agent and an immunomodulator. Less evidence is available on the use of anti-integrins in pregnancy; however, the current data suggest they may be safe as well. Conversations about a patient's desire for pregnancy should occur between the patient and provider on a regular basis prior to conception and particularly with any change in disease activity or change in the treatment regimen. This chapter will review the current evidence on the safety of IBD medications during pregnancy and lactation so that providers can more easily discuss the importance of medication adherence for disease remission with their patients who are contemplating conception.
Virginia Commonwealth University and McGuire VA Medical Center, GI / Hepatology Service (111-N)1201 Broad Rock Boulevard Richmond, Richmond, VA, 23249, USA.
Jill K J
JK
Gaidos
Mayo Clinic, 200 First St. SW Rochester, Rochester, MN, 55905, USA. Kane.Sunanda@mayo.edu.
Sunanda V
SV
Kane
Crohn’s disease; Immunomodulators; Inflammatory bowel disease; Lactation; Pregnancy; Ulcerative colitis